Raul Borges Nascimento, Suelly Maria Mendes Ribeiro, Nathalia Carolina Fernandes Fagundes, David Normando
{"title":"儿童和青少年接受生长激素治疗的颅面改变:一项系统综述。","authors":"Raul Borges Nascimento, Suelly Maria Mendes Ribeiro, Nathalia Carolina Fernandes Fagundes, David Normando","doi":"10.1111/ocr.12937","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this systematic review was to investigate the association between craniofacial changes and growth hormone (GH) therapy among children and adolescents with GH deficiency or idiopathic short stature (ISS). The PRISMA guideline was followed to carry out all stages of this review. An electronic search was conducted in seven databases, without year or language restrictions. The study selection was carried out in two stages by two calibrated examiners. Studies exploring craniofacial changes among children and adolescents with GH deficiency or ISS undergoing GH therapy were included. After data extraction, the risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal tool and the RoB 2.0 Checklist. The certainty of the evidence was assessed using the GRADE tool. Among the 4494 identified citations, seven studies met the eligibility criteria. These studies evaluated the impact of GHs on cephalometric measurements and dental age. No differences between immediate and delayed treatments were found in maxillary and mandibular dimensions. All selected articles showed a low risk of bias. A low certainty of evidence was observed for all outcomes assessed. GH therapy appears to result in a small increase in mandibular dimensions, although without clinical significance characteristic of adverse effects. Clinical trials and long-term follow-up studies of these patients are needed to develop accurate recommendations regarding the effects of GHs in the craniofacial region. Growth hormone may result in a slight increase in mandibular and maxillary dimensions, without significant adverse effects to general health. Controlled intervention studies with long-term follow-up are needed to establish more precise recommendations. Trial Registration: PROSPERO database (https://www.crd.york.ac.uk/prospero/): CRD42024511329.</p>","PeriodicalId":19652,"journal":{"name":"Orthodontics & Craniofacial Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Craniofacial Changes Among Children and Adolescents Submitted to Growth Hormone Therapy: A Systematic Review.\",\"authors\":\"Raul Borges Nascimento, Suelly Maria Mendes Ribeiro, Nathalia Carolina Fernandes Fagundes, David Normando\",\"doi\":\"10.1111/ocr.12937\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The aim of this systematic review was to investigate the association between craniofacial changes and growth hormone (GH) therapy among children and adolescents with GH deficiency or idiopathic short stature (ISS). The PRISMA guideline was followed to carry out all stages of this review. An electronic search was conducted in seven databases, without year or language restrictions. The study selection was carried out in two stages by two calibrated examiners. Studies exploring craniofacial changes among children and adolescents with GH deficiency or ISS undergoing GH therapy were included. After data extraction, the risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal tool and the RoB 2.0 Checklist. The certainty of the evidence was assessed using the GRADE tool. Among the 4494 identified citations, seven studies met the eligibility criteria. These studies evaluated the impact of GHs on cephalometric measurements and dental age. No differences between immediate and delayed treatments were found in maxillary and mandibular dimensions. All selected articles showed a low risk of bias. A low certainty of evidence was observed for all outcomes assessed. GH therapy appears to result in a small increase in mandibular dimensions, although without clinical significance characteristic of adverse effects. Clinical trials and long-term follow-up studies of these patients are needed to develop accurate recommendations regarding the effects of GHs in the craniofacial region. Growth hormone may result in a slight increase in mandibular and maxillary dimensions, without significant adverse effects to general health. Controlled intervention studies with long-term follow-up are needed to establish more precise recommendations. Trial Registration: PROSPERO database (https://www.crd.york.ac.uk/prospero/): CRD42024511329.</p>\",\"PeriodicalId\":19652,\"journal\":{\"name\":\"Orthodontics & Craniofacial Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orthodontics & Craniofacial Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ocr.12937\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthodontics & Craniofacial Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ocr.12937","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
Craniofacial Changes Among Children and Adolescents Submitted to Growth Hormone Therapy: A Systematic Review.
The aim of this systematic review was to investigate the association between craniofacial changes and growth hormone (GH) therapy among children and adolescents with GH deficiency or idiopathic short stature (ISS). The PRISMA guideline was followed to carry out all stages of this review. An electronic search was conducted in seven databases, without year or language restrictions. The study selection was carried out in two stages by two calibrated examiners. Studies exploring craniofacial changes among children and adolescents with GH deficiency or ISS undergoing GH therapy were included. After data extraction, the risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal tool and the RoB 2.0 Checklist. The certainty of the evidence was assessed using the GRADE tool. Among the 4494 identified citations, seven studies met the eligibility criteria. These studies evaluated the impact of GHs on cephalometric measurements and dental age. No differences between immediate and delayed treatments were found in maxillary and mandibular dimensions. All selected articles showed a low risk of bias. A low certainty of evidence was observed for all outcomes assessed. GH therapy appears to result in a small increase in mandibular dimensions, although without clinical significance characteristic of adverse effects. Clinical trials and long-term follow-up studies of these patients are needed to develop accurate recommendations regarding the effects of GHs in the craniofacial region. Growth hormone may result in a slight increase in mandibular and maxillary dimensions, without significant adverse effects to general health. Controlled intervention studies with long-term follow-up are needed to establish more precise recommendations. Trial Registration: PROSPERO database (https://www.crd.york.ac.uk/prospero/): CRD42024511329.
期刊介绍:
Orthodontics & Craniofacial Research - Genes, Growth and Development is published to serve its readers as an international forum for the presentation and critical discussion of issues pertinent to the advancement of the specialty of orthodontics and the evidence-based knowledge of craniofacial growth and development. This forum is based on scientifically supported information, but also includes minority and conflicting opinions.
The objective of the journal is to facilitate effective communication between the research community and practicing clinicians. Original papers of high scientific quality that report the findings of clinical trials, clinical epidemiology, and novel therapeutic or diagnostic approaches are appropriate submissions. Similarly, we welcome papers in genetics, developmental biology, syndromology, surgery, speech and hearing, and other biomedical disciplines related to clinical orthodontics and normal and abnormal craniofacial growth and development. In addition to original and basic research, the journal publishes concise reviews, case reports of substantial value, invited essays, letters, and announcements.
The journal is published quarterly. The review of submitted papers will be coordinated by the editor and members of the editorial board. It is policy to review manuscripts within 3 to 4 weeks of receipt and to publish within 3 to 6 months of acceptance.